Strumento inattivo

Azioni Receptos Inc

Azioni

Prezzo di chiusura Nasdaq Altri mercati azionari
- ^USD	-

Receptos : Results of the Phase 2 TOUCHSTONE Trial - Report on Receptos, Inc.	22/07/15
Receptos : Celgene to Acquire Receptos, Advancing Leadership in Immune-Inflammatory Diseases	17/07/15
Receptos : Ryan & Maniskas, LLP : Investigation of Receptos, Inc.	17/07/15
Receptos : Law Firm Kirby McInerney LLP Investigating Potential Claims on Behalf of Receptos, Inc. Stockholders	16/07/15
Bank of America : Wall Street edges lower as energy weighs	15/07/15

Dirigenti	Titolo	Età	Da
Peter Kellogg DFI	Director of Finance/CFO	67	-
Brian Feagan PRN	Corporate Officer/Principal	-	-
Krzysztof Selmaj PRN	Corporate Officer/Principal	-	-

Amministratori	Titolo	Età	Da
John Weiland BRD	Director/Board Member	68	15/02/18

Settore

	Variaz. 1 gen.	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+9,42%	114 Mrd
REGENERON PHARMACEUTICALS, INC.	+11,84%	104 Mrd
BIONTECH SE	-14,15%	22,41 Mrd
ARGENX SE	-1,05%	22,28 Mrd
GENMAB A/S	-5,29%	19,07 Mrd
WUXI APPTEC CO., LTD.	-38,29%	18 Mrd
BEIGENE, LTD.	-4,16%	17,89 Mrd
NEUROCRINE BIOSCIENCES, INC.	+7,99%	14,28 Mrd
SAREPTA THERAPEUTICS, INC.	+36,24%	12,55 Mrd